Transcription Factor Runx1 Activates Opn to Promote Tumor Progression in Head and Neck Cancer
Abstract Background:Metastatic progression remains a major burden for head and neck squamous cell carcinoma (HNSCC). Runt-related transcription factor 1 (RUNX1)has been reported to be associated with an aggressive phenotype in several cancers. However, the precise roles of RUNX1 underlying the metastaticprogression of HNSCC remain largely unknown.Methods:RUNX1 expression levels in HNSCC cells and tissues were detected by quantitative real-time PCR (qPCR), Western blottingand immunohistochemistry (IHC). In vitro and in vivo assays were performed to investigate the function of RUNX1 in the metastatic phenotype and the tumorigenic capability of HNSCC cells. Luciferase reporter and chromatin immunoprecipitation (ChIP)-qPCR assays were performed to determine the underlying mechanism of RUNX1-mediated HNSCC aggressiveness.Results:RUNX1 was increased with disease progression in patients withHNSCC.Furthermore, we found that silencing ofRUNX1 significantly decelerated the malignant progression of HNSCC cells and reduced Osteopontin (OPN) expression in vitro, and weakened the tumorigenicityof HNSCC cells in vivo. Mechanistically, we demonstrated that RUNX1 played an important role in activating MAPK signaling by directly binding to the promoter of OPN.Conclusions: Our results provide new insight into the mechanisms underlying the facilitate metastasisability of RUNX1and reveal the therapeutic potential of targeting RUNX1 in HNSCC.